ArticlePLoS neglected tropical diseases2026
CD163⁺ monocytes and soluble CD163 as prognostic indicators in severe fever with thrombocytopenia syndrome: An integrative analysis.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere fever with thrombocytopenia syndrome (SFTS) carries high short-term mortality and lacks approved antiviral therapy, highlighting the need for admission risk tools grounded in upstream host immune pathobiology.
methodsPublic single-cell RNA sequencing (scRNA-seq) data (GSE175499) from 15 SFTS patients (4 non-survivors, 11 survivors) and 4 healthy controls were reanalyzed to map cell-cell communication and identify monocyte subsets and pathways. Findings were validated by bulk RNA sequencing and flow cytometry. A multicenter clinical cohort (n = 150, 132 survivors and 18 non-survivors) measured admission sCD163 using enzyme-linked immunosorbent assay (ELISA) and assessed 30-day mortality using area under the curve (AUC), Kaplan-Meier, and Cox models.
resultsSingle-cell analysis identified expansion of CD163 ⁺ intermediate monocytes in SFTS, along with antiviral and complement activation programs in non-survivors. Communication analysis prioritized thrombospondin (THBS) signaling with the dominant sender shifting from CD163 ⁺ intermediate (survivors) to CD163 ⁺ classical monocytes (non-survivors). Flow cytometry confirmed increased CD163 ⁺ monocytes in SFTS. At admission, sCD163 independently predicted 30-day mortality (optimal threshold = 1.17 µg/mL, AUC 0.80). A two-marker model combining sCD163 with blood urea nitrogen (BUN) improved discrimination (AUC 0.87), yielded stepwise separation across three risk tiers (Score 0, 1, and 2) and replicated externally (AUC 0.73 and 0.83). Elevated sCD163 was consistently associated with higher mortality across sex and age subgroups. However, further subgroup analyses within the three-tier risk score were limited by small sample sizes and should be considered exploratory.
conclusionsWe identified and orthogonally validated CD163 ⁺ monocyte programs linked to outcomes, establishing admission serum sCD163 as a biomarker. An admission two-marker score (sCD163 and BUN) provides a simple three-tier admission score that rapidly stratifies 30-day mortality risk and guides intensified monitoring and timely supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.